Loading clinical trials...
Loading clinical trials...
A Phase II Study to Evaluate the Safety and Efficacy of Ex Vivo Expanded Autologous Immune Killer Cells (IKC) in Stage IV Non-small Cell Lung Cancer (NSCLC) in Patients Who Failed Chemotherapy or Target Therapy
Conditions
Interventions
Immune Killer Cells (IKC)
Locations
2
Taiwan
Taipei Veterans General Hospital
Taipei, Taiwan
Tri Service General Hospital
Taipei, Taiwan
Start Date
December 5, 2017
Primary Completion Date
February 16, 2020
Completion Date
February 16, 2020
Last Updated
April 16, 2020
Lead Sponsor
Ivy Life Sciences, Co., Ltd
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions